公开(公告)号：US20240342184A1

公开(公告)日：2024-10-17

申请号：US18757557

申请日：2024-06-28

Applicant: CHINA PHARMACEUTICAL UNIVERSITY

Inventor： Haiping HAO ,  Hong WANG ,  Huiyong SUN ,  Huijian HU ,  Xiaojie PAN ,  Guangji WANG ,  Xiaowei XU ,  Shuang CUI

IPC: A61K31/53 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K47/26 ,  A61K47/32 ,  A61P1/16

CPC classification number: A61K31/53 ,  A61K9/08 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/26 ,  A61K47/32 ,  A61P1/16

Abstract: Provided in the present invention is the use of an enhancer named as 3C1 in the preparation of an enhancer for the interaction between FXR protein and Caspase 8 protein. The enhancer can promote the interaction between FXR protein and Caspase 8 protein, thereby inhibiting the recruitment of Caspase 8 to apoptosome and blocking its formation, inhibiting the cleavage and activation of Caspase 8, blocking signal transduction of apoptosis, and ultimately inhibiting cell apoptosis. Therefore, the enhancer can be used for preparing a drug for treating liver diseases characterized with hepatocyte apoptosis.

公开(公告)号：US20200368199A1

公开(公告)日：2020-11-26

申请号：US16960226

申请日：2019-11-22

Applicant: CHINA PHARMACEUTICAL UNIVERSITY

Inventor： Haiping HAO ,  Hong WANG ,  Jiyu ZHOU ,  Guangji WANG ,  Shuang CUI ,  Xiaojie PAN ,  Yitong GUO ,  Ningning HUANG

IPC: A61K31/357 ,  A61K31/201 ,  A61K31/55 ,  A61K31/42 ,  A61K31/575

Abstract: A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.